Display options
Cite
Secchiero P, Voltan R, Rimondi E, et al. The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. Oncotarget. 2017;8(35):59235-59245doi: 10.18632/oncotarget.19494.
Secchiero, P., Voltan, R., Rimondi, E., Melloni, E., Athanasakis, E., Tisato, V., Gallo, S., Rigolin, G. M., & Zauli, G. (2017). The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. Oncotarget, 8(35), 59235-59245. https://doi.org/10.18632/oncotarget.19494
Secchiero, Paola, et al. "The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells." Oncotarget vol. 8,35 (2017): 59235-59245. doi: https://doi.org/10.18632/oncotarget.19494
Secchiero P, Voltan R, Rimondi E, Melloni E, Athanasakis E, Tisato V, Gallo S, Rigolin GM, Zauli G. The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. Oncotarget. 2017 Jul 22;8(35):59235-59245. doi: 10.18632/oncotarget.19494. eCollection 2017 Aug 29. PMID: 28938632; PMCID: PMC5601728.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 22;8(35):59235-59245. doi: 10.18632/oncotarget.19494. eCollection 2017 Aug 29.

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.

Oncotarget

Paola Secchiero, Rebecca Voltan, Erika Rimondi, Elisabetta Melloni, Emmanouil Athanasakis, Veronica Tisato, Stefania Gallo, Gian Matteo Rigolin, Giorgio Zauli

Affiliations

  1. Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.
  2. Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
  3. Department of Medical Sciences, Section of Hematology, University of Ferrara, Ferrara, Italy.

PMID: 28938632 PMCID: PMC5601728 DOI: 10.18632/oncotarget.19494

Abstract

Ibrutinib blocks B-cell receptor signaling and interferes with leukemic cell-to-microenvironment interactions. Ibrutinib plays a key role in the management of B-CLL and is recommended for first line treatment of high-risk CLL patients with 17p deletion. Therefore, elucidating the factors governing sensitivity/resistance to Ibrutinib represents a relevant issue. For this purpose, in 3 B-CLL patient samples harboring functional

Keywords: B-leukemic cells; Ibrutinib; NOTCH1; combination therapy; γ-secretase inhibitors

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

References

  1. Blood. 2011 Oct 20;118(16):4313-20 - PubMed
  2. Cancer Cell. 2014 Mar 17;25(3):318-34 - PubMed
  3. Leukemia. 2013 Jul;27(7):1558-66 - PubMed
  4. Clin Cancer Res. 2017 Feb 15;23 (4):1049-1059 - PubMed
  5. Blood. 2011 Jan 13;117(2):563-74 - PubMed
  6. Pediatr Blood Cancer. 2012 May;58(5):815-8 - PubMed
  7. Blood. 2016 Sep 22;128(12 ):1609-13 - PubMed
  8. J Gen Virol. 1992 Feb;73 ( Pt 2):417-21 - PubMed
  9. Oncotarget. 2016 Nov 15;7(46):74807-74819 - PubMed
  10. Leukemia. 2016 Apr;30(4):833-43 - PubMed
  11. Leukemia. 2015 Jan;29(1):96-106 - PubMed
  12. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80 - PubMed
  13. N Engl J Med. 2013 Jul 4;369(1):32-42 - PubMed
  14. Blood. 1997 Feb 1;89(3):883-95 - PubMed
  15. Blood Cancer J. 2016 Jun 10;6:e434 - PubMed
  16. Blood. 2015 May 28;125(22):3432-6 - PubMed
  17. Lancet Oncol. 2015 Feb;16(2):169-76 - PubMed
  18. Cell Oncol (Dordr). 2011 Dec;34(6):545-51 - PubMed
  19. Haematologica. 2015 Jan;100(1):77-86 - PubMed
  20. Blood. 2009 Apr 30;113(18):4300-8 - PubMed
  21. Clin Cancer Res. 2015 Jan 1;21(1):60-7 - PubMed
  22. Oncotarget. 2016 Apr 5;7(14 ):18965-77 - PubMed
  23. Blood. 2015 Apr 16;125(16):2497-506 - PubMed
  24. Oncogene. 2015 May 7;34(19):2426-36 - PubMed
  25. Nature. 1985 Dec 12-18;318(6046):533-8 - PubMed
  26. N Engl J Med. 2014 Jun 12;370(24):2352-4 - PubMed
  27. N Engl J Med. 2015 Dec 17;373(25):2425-37 - PubMed
  28. Oncotarget. 2014 Dec 30;5(24):12635-45 - PubMed
  29. Lancet Oncol. 2014 Jan;15(1):48-58 - PubMed
  30. Leukemia. 2014 May;28(5):1060-70 - PubMed
  31. Bioorg Med Chem Lett. 2015 May 1;25(9):1905-9 - PubMed
  32. Leukemia. 2015 Oct;29(10):2003-14 - PubMed
  33. Clin Cancer Res. 2015 Oct 15;21(20):4642-51 - PubMed
  34. Stem Cells. 2008 Nov;26(11):2955-63 - PubMed
  35. Int J Cancer. 2013 Apr 15;132(8):1940-53 - PubMed
  36. Blood Cancer J. 2012 May;2(5):e73 - PubMed
  37. Oncotarget. 2016 Oct 25;7(43):70623-70638 - PubMed
  38. Blood. 2016 Jan 28;127(4):449-57 - PubMed
  39. Blood. 2014 Jun 26;123(26):4132-5 - PubMed
  40. Oncogene. 2017 Aug 10;36(32):4653-4661 - PubMed
  41. N Engl J Med. 2014 Jun 12;370(24):2286-94 - PubMed
  42. Nat Rev Genet. 2012 Sep;13(9):654-66 - PubMed
  43. Blood. 2009 Jan 22;113(4):856-65 - PubMed
  44. ACS Med Chem Lett. 2015 Mar 11;6(5):523-7 - PubMed
  45. Curr Pharm Des. 2008;14 (21):2100-10 - PubMed

Publication Types